COVID-19 has found statisticians advising on urban policy, global health policy and tech policy in ways that have transformed private sector relationships with the public sector. What are the long-term impacts of this transformation?

Cytel invites you to join us for a complimentary virtual panel discussion, where Dr. Natalia Muhlemann will lead a conversation with industry experts who have had to facilitate such collaboration in the past year.

Join this Panel to Learn:

  • The changes to the pharmaceutical industry that have arisen due to the pandemic and the long term impact of COVID-19 on clinical development.
  • The influence of the industry and the pandemic on urban policy, global health policy, and technology policy.
  • The changing role of statisticians in private sector decision-making and public policy.
  • Statistics, clinical research and the ethics of public health policy.


Dr. Natalia Muhlemann

Natasha frameNatalia Muhlemann, MD, MBA is VP, Strategic Consulting, Clinical Development, Regulatory, Market Access and Commercialization at Cytel. Natalia has over 18 years of experience in General Management, Business Development and Clinical Development in Life Sciences across several therapeutic areas. Natalia combines medical and strategic expertise enhancing business value through clinical and real world evidence generation, medical & scientific interactions and stakeholders' engagement. A passionate advocate for adaptive approaches to trial design, Natalia has been leading the integration of adaptive designs into comprehensive evidence development strategies that combine clinical, regulatory, market access and commercial plans.



Yuan Ji

YuanYuan Ji, Ph.D. is currently the Professor of Biostatistics (with tenure) at The University of Chicago. He has been serving the City of Chicago as an advisor during the pandemic.
Yuan spent 9 years at The University of Texas M.D. Anderson Cancer Centre, holding tenure-track and tenured faculty positions. He is internationally known for his work on designs of dose-finding trials, adaptive dose insertion, seamless and overlapping Phase I/II trials, immune-oncology studies, and subgroup enrichment approach. He is also an expert in bioinformatics and computational biology, with a deep understanding of translational medicine.

He has published over 100 peer-reviewed papers in top journals across different scientific disciplines, including Nature Methods, Journal of Clinical Oncology, and Journal of the National Cancer Institute.

Edward Mills

ed-1Ed Mills, Ph.D., is Vice President of Real World Evidence and Senior Principal Scientist at Cytel. He is also a Clinical Trials Advisor for the Gates Foundation. During the pandemic Ed’s team has designed and implemented clinical trials in low and middle-income countries, to ensure treatments are more widely accessible. Ed is also Professor of Global Health at McMaster University and has been published in a number of leading publications across statistics, global health and medicine.

Yannis Jemiai

Yannis_JemiaiYannis Jemiai, Ph.D., has a pivotal role within Cytel as Chief Scientific Officer where he has oversight for the corporate-level Scientific Agenda which includes establishing research portfolios in Bayesian, small sample, and other flexible designs; as well as complex innovative designs including adaptive trials, master protocols and MAMS. Yannis also has an extensive portfolio of research in adaptive trial design, financial and pharmaceutical strategy, decision theory, and regulatory affairs.